Core Points - Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. received a government subsidy of 19,322,657.00 yuan, which accounts for 42.07% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1] - The subsidy is classified as a revenue-related government grant and is associated with the company's regular business activities, expected to be recognized in the other income for the fiscal year 2025 [1] - The anticipated increase in the company's total profit for 2025 is 19,322,657.00 yuan, although the data is unaudited and the final accounting treatment will depend on the annual audit results [1]

证券代码：002826 证券简称：易明医药 公告编号：2025-060 西藏易明西雅医药科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、补助的确认、计量 根据《企业会计准则第16号——政府补助》的规定，公司收到与收益相关的 政府补助时，与企业日常活动相关的政府补助，按照经济业务实质，计入其他收 益或冲减相关成本费用，与企业日常活动无关的政府补助，计入营业外收入。 本次公司收到19,322,657.00元政府补助与收益相关，为与公司日常经营活 动相关的政府补助，计入2025年度其他收益，具体会计处理以年度审计机构审计 结果为准。 3、补助对上市公司的影响 1 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日收到政府补 助19,322,657.00元，占公司2024年度经审计归属于上市公司股东净利润的 42.07%。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府 ...

格隆汇9月16日丨易明医药(002826.SZ)公布，近日收到政府补助19,322,657.00元，占公司2024年度经审 计归属于上市公司股东净利润的42.07%。 ...

Group 1 - The company Yiming Pharmaceutical reported that as of September 10, 2025, the number of shareholders is 21,727 [2]

Group 1 - The core viewpoint of the news is that Yiming Pharmaceutical has shown significant stock performance, with a year-to-date increase of 91.39% and a recent trading volume indicating active market interest [1] - As of September 10, Yiming Pharmaceutical's stock price reached 19.64 CNY per share, with a total market capitalization of 3.745 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 1.4733 million CNY, with large orders contributing to 15.94% of total buying [1] Group 2 - Yiming Pharmaceutical's main business involves the research, production, and sales of chemical drugs (93.32% of revenue) and traditional Chinese medicine (6.10% of revenue) [1] - The company has been listed on the stock market since December 9, 2016, and has appeared on the trading leaderboard six times this year, with the latest occurrence on August 22, where it recorded a net purchase of 18.41 million CNY [1] - As of August 29, the number of shareholders decreased by 1.87% to 20,800, while the average circulating shares per person increased by 1.91% to 8,381 shares [2] Group 3 - For the first half of 2025, Yiming Pharmaceutical reported a revenue of 311 million CNY, reflecting a year-on-year decrease of 11.52%, and a net profit attributable to shareholders of 37.56 million CNY, down 5.27% year-on-year [2] - Since its A-share listing, the company has distributed a total of 114 million CNY in dividends, with 43.40 million CNY distributed over the past three years [3]

Core Viewpoint - Yiming Pharmaceutical (002826) is undergoing a board restructuring following the completion of its third board term, marking the first adjustment since the entry of 58.com founder Yao Jinbo into the company [1][4] Group 1: Board Restructuring - The new fourth board will consist of 7 directors, down from 8, including 3 independent directors, 3 non-independent directors, and 1 employee director [2] - All independent and non-independent directors from the previous board will be replaced [2] - Candidates for non-independent directors include Fu Lihua, Huang Lingyi, and Yao Yan, with backgrounds in management and education technology [2][3] Group 2: Shareholding Changes - Beijing Fuhao is expected to secure all non-independent director positions, indicating a new era under Yao Jinbo's leadership [4] - In May, Beijing Fuhao signed a share transfer agreement to acquire 23% of Yiming Pharmaceutical's shares from the former controlling shareholder, Gao Fan, at a price of 15.10 yuan per share, totaling 662 million yuan [4] Group 3: Company Overview - Yiming Pharmaceutical primarily engages in drug sales and promotion services, with a focus on cardiovascular and diabetes-related products [4] - The company's core product, Miglitol tablets, holds a leading market share in the domestic Miglitol market for type 2 diabetes treatment [4] - The company has maintained stable annual revenues of approximately 650 million yuan over the past two years [4] Group 4: Market Implications - Yao Jinbo's entry into the pharmaceutical industry has generated significant market interest regarding the potential resources and advantages he may bring to the company [5] - Beijing Fuhao has expressed intentions to leverage its strengths in investment management and industry planning to empower the company's business development [5]

Group 1 - The company held its 27th temporary board meeting on September 2, 2025, to conduct the board member election process as the current term has expired [1][2] - The fourth board will consist of 7 members, including 3 independent directors, 3 non-independent directors, and 1 employee director [1] - The board proposed the election of three non-independent directors: Fu Lihua, Huang Lingyi, and Yao Yan, with unanimous approval from all 7 attending board members [2][3] Group 2 - The board also proposed the election of three independent directors: He Deming, Chen Yan, and Wang Guangying, with unanimous approval from all 7 attending board members [3][9] - The independent director candidates have met the qualifications required by the Shenzhen Stock Exchange and will be submitted for approval at the upcoming shareholder meeting [3][9] - The fourth independent directors' term will last for three years starting from the date of election approval at the shareholder meeting [3][9] Group 3 - The company plans to hold the 2025 second temporary shareholder meeting on September 19, 2025, at 14:00 [4] - The meeting will include the election of the new board members using a cumulative voting system [4] - The resumes of the nominated candidates for both independent and non-independent directors are attached for reference [4][8]

Group 1 - The candidate, He Deming, has been nominated as an independent director for the fourth board of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and has confirmed understanding and agreement with the nomination [1] - The candidate declares that there are no relationships that could affect his independence and meets the qualifications required by relevant laws and regulations [1][2] - The candidate has passed the qualification review by the nomination committee of the company's third board and has no interests that could influence his independent performance [1][2] Group 2 - The candidate affirms compliance with the requirements of the Company Law of the People's Republic of China regarding eligibility to serve as a director [2] - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2] - The candidate confirms that serving as an independent director will not violate any relevant regulations, including those from the Central Commission for Discipline Inspection and the Ministry of Education [2][3] Group 3 - The candidate has no direct or indirect shareholding of more than 1% in the company or its major shareholders [5] - The candidate and immediate family members do not hold positions in the company or its subsidiaries [5][6] - The candidate has not been subject to any disqualifications or penalties by the China Securities Regulatory Commission or other regulatory bodies [7][8] Group 4 - The candidate commits to fulfilling the responsibilities of an independent director and ensuring that all statements and materials provided are true and complete [9][10] - The candidate will report any changes in eligibility to the board and will resign if any disqualifying conditions arise [9] - The candidate authorizes the company to disclose this declaration and related information to the Shenzhen Stock Exchange [10]

Group 1 - The company has nominated Chen Yan as a candidate for the independent director of its fourth board, and the nominee has agreed to this nomination [1] - The nomination was made after a thorough understanding of the nominee's professional background, education, qualifications, and any potential conflicts of interest [1] - The nominee has passed the qualification review by the company's third board nomination committee, confirming no close relationships that could affect independent performance [2] Group 2 - The nominee meets the qualifications and independence requirements set by relevant laws, regulations, and the Shenzhen Stock Exchange [2][3] - The nominee has participated in training and obtained relevant certification recognized by the stock exchange [2] - The nominee does not have any disqualifying conditions as per the Company Law of the People's Republic of China [2] Group 3 - The nominee has no significant business dealings with the company or its controlling shareholders [7] - The nominee has not been subject to any market entry bans by the China Securities Regulatory Commission [8] - The nominee has not received any public reprimands from the stock exchange in the last thirty-six months [8]

Group 1 - The candidate Chen Yan has been nominated as an independent director for the fourth board of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and has confirmed understanding and agreement with the nomination [1] - The candidate declares that there are no relationships that could affect independence and meets the qualifications required by relevant laws and regulations [1][2] - The candidate has passed the qualification review by the nomination committee of the company's third board and has no interests or relationships that could influence independent performance [1][2] Group 2 - The candidate affirms compliance with the requirements of the Company Law of the People's Republic of China regarding eligibility to serve as a director [2][3] - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2][3] - The candidate confirms that serving as an independent director will not violate any relevant regulations, including those from the Central Commission for Discipline Inspection and the Ministry of Education [2][3][4] Group 3 - The candidate has no direct or indirect shareholding of more than 1% in the company and is not among the top ten shareholders [5][6] - The candidate and immediate family members do not hold positions in the company or its subsidiaries [5][6] - The candidate has no significant business dealings with the company or its controlling shareholders [6][7] Group 4 - The candidate has not been subject to any disqualifications or penalties by the China Securities Regulatory Commission or the stock exchange [7][8] - The candidate has not been publicly reprimanded by the stock exchange in the last thirty-six months [8][9] - The candidate has not served as an independent director in more than three domestic listed companies [9][10]